Vesugen is a synthetic tripeptide, lysine-glutamic acid-aspartic acid (KED), studied as a vascular bioregulator by Russian gerontologist Vladimir Khavinson and his research group. Its best-supported effects are on vascular endothelial cells, the tissue layer that lines every blood vessel and controls blood flow, clotting, and vessel repair.
The research is real but narrow. Almost every study on Vesugen comes from the same research network in St. Petersburg, the human data is limited to two small observational reports, and no Western lab has independently replicated the peptide’s proposed DNA-binding mechanism. This guide separates what the studies actually measured from the marketing language built on top of them.
Key Takeaways
The Short Version
Vesugen is a lab-made tripeptide (KED) studied for its effects on vascular endothelial cells, the tissue lining blood vessels.
Cell studies show it can normalize endothelin-1, restore cell-to-cell connections called connexins, and activate the Ki-67 proliferation gene.
Human evidence is limited to two small, uncontrolled Russian studies, in patients with vascular disease and general polymorbidity.
Vesugen is a research compound, not an FDA-regulated supplement, and it is a different formula from BioLongevity’s natural blood vessel bioregulator.
What Is Vesugen (KED)?
Vesugen is a synthetic tripeptide built from three amino acids, lysine, glutamic acid, and aspartic acid, abbreviated KED. It belongs to a class of short peptides called cytogens, lab-synthesized molecules designed to mimic naturally occurring tissue peptides.
Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology developed Vesugen as part of a decades-long research program on organ-specific short peptides. The vascular version, KED, is one of dozens of tripeptides in that program, each proposed to act on a different tissue system.
Vesugen is sold in Russia as a food supplement and by research-peptide suppliers elsewhere. It is not an FDA-approved drug and is not currently sold as a regulated dietary supplement in the United States.
How Vesugen Works in Vascular Cells
Vesugen’s proposed mechanism is epigenetic. Instead of binding a receptor on the cell surface, short peptides like KED are thought to enter the cell nucleus and interact with DNA promoter regions that switch specific genes on or off.
In cultured human vascular endothelial cells, KED normalized the expression of endothelin-1, a signaling molecule that rises during atherosclerosis and contributes to vessel constriction [1]. The same research found that KED restored the expression of connexins, proteins that let neighboring endothelial cells communicate, and increased sirtuin-1, a protein tied to DNA repair and cellular aging [1].
A separate molecular docking study found that KED binds directly to a core promoter region of the MKI67 gene, which codes for Ki-67, a marker of cell proliferation [2]. Cell cultures treated with KED showed higher Ki-67 expression than untreated aged cultures, suggesting the peptide may help aging endothelial cells regain some capacity to divide and repair vessel damage [2].
None of this happens in a living human circulatory system in these particular studies. It happens in cultured cells and computer models, which is a meaningfully earlier stage of evidence than a clinical trial.
Vesugen Peptide Benefits Backed by Research
Vesugen’s benefits break down into five areas, and each rests on a different quality of evidence. The table below tiers them honestly.
| Claimed benefit | Strongest evidence available | What the study measured |
|---|---|---|
| Endothelial repair and vessel signaling | Human cell culture | Normalized endothelin-1, restored connexins, raised sirtuin-1 [1] |
| Blood flow in vascular disease | Small human observational study | Penile arterial blood flow in 41 patients with vasculogenic erectile dysfunction linked to atherosclerosis [3] |
| Biological aging markers | Small human observational study | Aging biomarkers in 32 patients with chronic polymorbidity [4] |
| Neuroprotection and memory | Review of in vitro and human reports | Dendritic spine restoration in cell models, plus reported memory and attention changes in elderly patients [5][6] |
| Cellular senescence | In vitro | Reduced p21 and beta-galactosidase, markers of aging cells, alongside the peptide AEDG [7] |
Endothelial Repair and Vascular Signaling
This is Vesugen’s core, best-supported research area. In cultured endothelial cells exposed to conditions that mimic atherosclerosis and restenosis, KED normalized elevated endothelin-1 and restored the connexin-based communication between cells that breaks down with vascular disease [1].
The same research ties this to sirtuin-1, a protein involved in DNA repair that tends to decline with age [1]. Researchers proposed that KED’s effect on Ki-67 gene expression, confirmed through molecular docking to the MKI67 promoter, is the mechanism behind these changes [2].
Blood Flow in Vascular Disease
The most cited human data on Vesugen comes from a Russian observational study in 41 older men with vasculogenic erectile dysfunction linked to atherosclerosis of the lower limbs [3]. Researchers measured blood flow in the penile arteries before and after Vesugen monotherapy using Doppler ultrasound and reported improvement.
This study had no placebo group, no blinding, and used a locally developed outcome scale, so it doesn’t meet the bar of a modern randomized controlled trial. It’s best read as a preliminary signal that a Vesugen formulation affected blood flow in one small, specific patient group, not as proof the peptide works for vascular disease broadly.
Biological Aging and General Health Markers
A second small study followed 32 patients aged 41 to 83 with chronic polymorbidity, meaning multiple overlapping health conditions, and residual organic brain syndrome [4]. Researchers tracked biological aging markers and reported tissue-supportive changes alongside another Khavinson peptide, Pinealon.
Like the vascular study, this research used a small sample without a placebo arm, and it comes from the same research network that developed the peptide.
Neuroprotection and Memory
Vesugen’s research footprint extends beyond blood vessels into neuroprotection, likely because vascular health and brain aging are closely linked. In a cell model of Alzheimer’s disease, KED increased the number of mushroom-shaped dendritic spines, structures tied to memory formation, by about 20% [6].
A 2021 review by the same research group also references oral KED use improving memory and attention scores in elderly patients with functional central nervous system disorders, though the review doesn’t describe that data as a controlled trial [5].
Cellular Senescence
A 2025 study using induced neurons found that KED, alongside the peptide AEDG, reduced markers associated with cell aging, including the cell-cycle marker p21 and beta-galactosidase activity [7]. Researchers described this as evidence the peptides may support neuronal differentiation and function as geroprotectors, the term Khavinson’s group uses for compounds studied for cellular anti-aging effects.
Where the Evidence Is Thin
Vesugen research has real limits, and they deserve equal billing with the benefits.
- Nearly every mechanistic and clinical study traces back to Khavinson-affiliated researchers in St. Petersburg. Independent replication outside that group is essentially absent.
- The proposed DNA-binding mechanism relies on molecular docking simulations, a computational prediction, not confirmed crystallographic or biophysical binding data.
- Both human reports are small, uncontrolled, and unblinded. Neither meets the design standards used to evaluate modern pharmaceuticals or supplements.
- No human pharmacokinetic data exists for Vesugen. How much of an oral dose is absorbed, and how it’s distributed in the body, hasn’t been characterized.
None of this means the research is worthless. It means Vesugen sits at an early, promising stage of investigation rather than a proven one, and claims that go beyond what these studies measured are getting ahead of the evidence.
Beyond the Clinical Evidence
Origin from Ventfort. Vesugen’s sequence (Lys-Glu-Asp) was identified through amino acid analysis of Ventfort, the natural blood-vessel peptide complex. Vesugen is the synthesized, defined-sequence version of that analysis, the same pattern used to derive Epitalon from the natural pineal complex and Pinealon from the same source.
Regulatory status. Vesugen has not been registered as a pharmaceutical drug in Russia or elsewhere. It is sold as a food/dietary supplement.
Mechanism consistency across the peptide family. The gene-promoter-binding model used to explain Vesugen’s endothelin-1 and Ki-67 effects has also been tested, using similar molecular-docking and in vitro methods, for other short peptides in the same research program, including EDR, AEDG, and KE. Vesugen’s findings fit a pattern that shows up repeatedly across this peptide family rather than standing alone.
Commercial use history. Vesugen has been sold by international peptide retailers for over a decade. No adverse-event reports have been publicized. There’s no formal post-market surveillance system, comparable to FDA MedWatch, tracking supplement-specific adverse events for products like this one, so that absence of reports isn’t backed by the kind of systematic tracking a drug would have.
Vesugen vs. BioLongevity’s Vascular Peptide Bioregulators
Vesugen is a research compound. It isn’t manufactured, tested, or sold by BioLongevity Supplements, and it isn’t evaluated by the FDA as a dietary supplement in the United States.
BioLongevity offers BioBloodVessels, a peptide bioregulator built around a naturally derived blood vessel peptide complex rather than the synthetic KED tripeptide. It targets the same general body system, vascular tissue, but it’s a distinct formula with its own third-party testing and Certificate of Analysis.
Readers researching organ-specific peptide bioregulators as a category may want to start with a formula that’s manufactured under U.S. GMP standards and independently verified batch by batch, rather than a research-only compound with no established human dosing.
Frequently Asked Questions
What is Vesugen made of?
Vesugen is a synthetic tripeptide made from three amino acids: lysine, glutamic acid, and aspartic acid, abbreviated KED.
Is Vesugen the same as Ventfort?
No. Ventfort is a natural peptide complex extracted from vascular tissue, while Vesugen is a lab-synthesized tripeptide designed to mimic a smaller fragment of similar signaling activity. Both are studied for vascular support, but they’re different formulas with separate research histories.
Has Vesugen been tested in a randomized controlled trial?
No published randomized controlled trial exists for Vesugen. The available human data comes from two small, uncontrolled observational studies conducted by the peptide’s original research group [3][4].
Is Vesugen FDA-approved?
No. Vesugen is not an FDA-approved drug and is not currently sold as a regulated dietary supplement in the United States.
What does the strongest Vesugen research actually show?
The strongest evidence sits at the cell level: normalized endothelin-1, restored connexin signaling, and increased Ki-67 and sirtuin-1 expression in cultured human vascular endothelial cells [1][2].
The Bottom Line on Vesugen
Vesugen has a genuine, if narrow, research base. The strongest findings are cellular: consistent effects on endothelin-1, connexins, sirtuin-1, and Ki-67 in vascular endothelial cells [1][2]. The human evidence is real but small, uncontrolled, and confined to two Russian observational studies [3][4].
If you’re exploring peptide bioregulators for vascular support as a category, it’s worth understanding what a formula’s actual research base does and doesn’t show before building it into a routine.
Curious how organ-specific peptide bioregulators fit into a broader longevity routine? Explore BioLongevity’s third-party tested bioregulator collection, including BioBloodVessels for vascular support.
Ask a qualified clinician before starting any supplement or research compound if you are pregnant, nursing, taking medication, or managing a medical condition. This article is educational and does not replace medical advice.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
References
[1] Kozlov KL, Bolotov II, Linkova NS, Drobintseva AO, Khavinson VK, Dyakonov MM, Kozina LS. Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis. Advances in Gerontology. 2016;29(4):646-650. PubMed
[2] Khavinson VKh, Tarnovskaya SI, Linkova NS, Gutop EO, Elashkina EV. Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging. Advances in Gerontology. 2014;27(1):108-114. PubMed
[3] Kitachev KV, Sazonov AB, Kozlov KL, et al. The efficacy of peptide bioregulators of vessels in lower limbs chronic arterial insufficiency treatment in old and elderly people. Advances in Gerontology. 2013;26(2):292-296. PubMed
[4] Meshchaninov VN, Tkachenko EL, Zharkov SV, Gavrilov IV, Katyreva IuE. Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission. Advances in Gerontology. 2015;28(1):62-67. PubMed